PACB (PacBio) EV/EBITDA Multiple
The price action of Pacific Biosciences (PACB) securities demonstrates a dependence on the implementation of DNA sequencing systems and R&D expenditures, with the EV/EBITDA ratio standing at 0.00. Pacific Biosciences (PACB) sources lasers and chips from partners while maintaining independence in its software. The business relies on diversification, providing solutions for the agricultural sector, medicine, and microbiology, which expands its customer base.
pacb.com (PACB) - metric breakdowns and financial figures
- current price and projected stock value:
- business market valuation indicators:
- issuer book value statistics:
- company liabilities and liquidity data:
- financial results and valuation multiples details:
PACB - Net Income|Projected Future Earnings Pacific Biosciences|PACB - Business Payback Period|Forward P/E Multiple Pacific Biosciences|PACB - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization PacBio Corp|PACB - Operating profit before amortization|Net earnings per share (EPS TTM) PacBio|PACB - Net earnings per share for the last 12 months|Quarterly EPS earnings growth pacb.com|PACB - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Pacific Biosciences
Comprehensive company analysis:PACB (Pacific Biosciences of California)
Pacific Biosciences operates a unique ecosystem of high-precision DNA sequencing, creating indispensable tools for cutting-edge science. By analyzing the business valuation via EV/EBITDA, an investor sees the ratio of the company's total enterprise value to its operating profit. This multiple accounts for debt load and taxes, determining the real value of assets relative to the generated cash flow. Low values indicate undervaluation, yet signal risks in the event of declining revenues.
Competitor analysis
EV/EBITDA Multiple TEM (tempus.com)|QGEN (Qiagen Corp) - Company Value to Operating Income Before Depreciation Ratio|Ionis Pharmaceuticals - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio repligen.com RGEN|RNA: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio CRISPR Therapeutics Inc|Enterprise Value to EBITDA Ratio WGS|RARE: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple BEAM|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization SRPT (sarepta.com)|EV/EBITDA Multiple TWST (Twist Bioscience, Inc.)|Total Company Value to Operating Income Before Depreciation Ratio 10x Genomics Inc (TXG)|NTLA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Stoke Corp|BioLife Solutions, Inc. (BLFS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|WVE - Total Company Value to Operating Income Before Depreciation Ratio|MAZE (Maze Therapeutics) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Sionna Therapeutics, Inc. (SION)|EV/EBITDA Multiple PRME|Total Company Value to Operating Income Before Depreciation Ratio Taysha Corp|EV/EBITDA Multiple QURE (uniQure N.V.)|meiragtx.com (MGTX) - Company Value to EBITDA|RGNX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|SLDB (Solid Biosciences Inc) - Enterprise Value to Operating Income Before Depreciation|OCGN: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Benitec Corp|DSGN (Design Therapeutics) - EV/EBITDA Multiple|Company Value to EBITDA rocketpharma.com RCKT|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization 4D Molecular Therapeutics, Inc. (FDMT)|Total Company Value to Operating Income Before Depreciation Ratio lexeotx.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Korro Bio KRRO|EDIT (Editas Corp) - Company Value to Operating Income Before Depreciation Ratio|Silence Therapeutics - EV/EBITDA Multiple|PRQR - EV/EBITDA Multiple|CDXS: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Sangamo Therapeutics Inc.|NAUT (Nautilus Biotechnology, Inc.) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization MGX|EV/EBITDA Multiple DTIL|generationbio.com - Enterprise Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Boundless Bio BOLD|XCUR: Enterprise Value to Operating Income Before Depreciation|Celsion Corporation - EV/EBITDA Multiple|PHIO - EV/EBITDA Multiple|mustangbio.com (MBIO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio RNAZ (TransCode Therapeutics, Inc.)|BNGO (Bionano Genomics Inc.) - EV/EBITDA Multiple|EV/EBITDA Multiple Applied DNA Sciences Inc|EV/EBITDA Multiple BLUE|Enterprise Value to EBITDA Ratio immunoprecise.com IPA|EV/EBITDA Multiple OMGA (Omega Therapeutics)|Total Company Value to Operating Income Before Depreciation Ratio singulargenomics.com (OMIC)|Regulus Therapeutics Inc. - EV/EBITDA Multiple|Company Value to Operating Income Before Depreciation Ratio SYRS|TBIO: EV/EBITDA Multiple|TCON - Total Company Value to Operating Income Before Depreciation Ratio|UBX (Unity Biotechnology) - EV/EBITDA Multiple
